Learn more about MDS at http://www.YouAndMDS.com
MDS expert Rafael Bejar, MD, PhD, explains how mutationdriven treatments for myelodysplastic syndromes (MDS) target changes on specific genes such as IDH1 or IDH2. Other examples include the use of lenalidomide, chromosome deletions in 5q as potential drivers for treatment, and treatments targeted to mutations in the gene FLT3 are present.